GE Vernova Inc vs Revvity Inc — how do they compare? GE Vernova Inc trades at $1,004.73 (market cap $266.16B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: GE Vernova Inc is far larger — about 15.7× Revvity Inc's market cap, and GE Vernova Inc pays the higher dividend (0.2%). Which is the better fit depends on your goals — on Pluang, investors hold GE Vernova Inc for 36 Days and Revvity Inc for 12 Days on average.
| GEV | RVTY | |
|---|---|---|
Market Cap | $266.16B | $16.98B |
Volume | 2,324,165 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $1.17K | $157.36 |
52-Week Low | $547.96 | $82.26 |
Typical Hold Time | 36 Days | 12 Days |
Enterprise Value | $255.83B | $19.30B |
Dividend Yield | 0.2% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
GE Vernova (GEV) trades at $999.35, up 0.23% with strong bullish technical signals and positive analyst sentiment. The stock shows impressive fundamentals with 91.48% ROE and 23.04% net margin, though valuation metrics appear elevated with P/E of 28.65 and EV/EBITDA of 85.22. Recent news highlights the company securing the first US construction permit for its BWRX-300 small modular reactor and benefiting from AI-driven power demand growth.
GEV presents growth potential from its $176 billion backlog and AI infrastructure demand, but faces valuation concerns and execution risks in its wind power segment. Analyst consensus remains strongly bullish with 75.86% buy ratings and $1,270 price target, representing 27% upside from current levels. Key risks include competitive pressures and the challenge of maintaining current premium valuation multiples.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →